MDLN

Pomerantz LLP is investigating Medline Inc. for potential securities fraud following an FDA warning letter in June 2026 detailing significant manufacturing violations. The company's stock fell 7.16% on the FDA announcement and an additional 12.79% in August when Medline disclosed that remediation efforts resulted in earnings losses.

Pomerantz LLP is investigating Medline Inc. for potential securities fraud following an FDA warning letter in June 2026 detailing significant manufacturing violations. The company's stock fell 7.16% on the FDA announcement and another 12.79% in August when Medline disclosed that remediation efforts resulted in earnings losses.

Law firm Kirby McInerney LLP is investigating Medline Inc. for potential federal securities law violations following an FDA warning letter in June 2026 detailing significant manufacturing practice violations. The company's stock declined 7.2% on the FDA announcement and another 12.8% in August after Medline disclosed earnings losses from remediation efforts including product recalls.

Law firm Bragar Eagel & Squire is investigating Medline Inc. for potential securities law violations following FDA warning letters regarding manufacturing practice violations. The company's stock declined 7.2% on June 2, 2026 after FDA warnings and another 12.8% on August 5, 2026 after the company disclosed earnings losses from remediation efforts including product recalls.